Euroopa Liit - norra - EMA (European Medicines Agency)

accord healthcare s.l.u. - sitagliptin hydrochloride - diabetes mellitus, type 2 - legemidler som brukes i diabetes - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Norra - norra - Statens legemiddelverk

piramal critical care b.v. - fentanylsitrat - injeksjonsvæske, oppløsning - 50 mikrog/ ml

Euroopa Liit - norra - EMA (European Medicines Agency)

piramal critical care b.v. - miglustat - gaucher sykdom - andre alimentary tract and metabolism products, - yargesa er angitt for den muntlige behandling av voksne pasienter med mild til moderat type 1-gaucher sykdom. yargesa kan bare bli brukt i behandlingen av pasienter som enzyme replacement therapy er uegnet. yargesa er angitt for behandling av progressive nevrologiske manifestasjoner hos voksne pasienter og paediatric pasienter med niemann-pick-type c-sykdom.

Norra - norra - Statens legemiddelverk

piramal critical care b.v. - sufentanilsitrat - injeksjonsvæske, oppløsning - 50 mikrog/ ml

Norra - norra - Statens legemiddelverk

piramal critical care b.v. - sufentanilsitrat - injeksjonsvæske, oppløsning - 5 mikrog/ ml

Norra - norra - Statens legemiddelverk

octapharma ab - immunglobulin, normalt, humant - injeksjonsvæske, oppløsning - 165 mg/ ml

Norra - norra - Statens legemiddelverk

octapharma (2) - immunglobulin, normalt (humant) - infusjonsvæske, oppløsning - 50 mg/ ml

Euroopa Liit - norra - EMA (European Medicines Agency)

instituto grifols s.a. - humant normalt immunglobulin - mucocutaneous lymph node syndrome; guillain-barre syndrome; bone marrow transplantation; purpura, thrombocytopenic, idiopathic; immunologic deficiency syndromes - immune sera og immunglobuliner, - replacement therapy in adults, children and adolescents (0-18 years) in: , primary immunodeficiency syndromes with impaired antibody production;, hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom prophylactic antibiotics have failed;, hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who failed to respond to pneumococcal immunisation;, hypogammaglobulinaemia in patients after allogenic haematopoietic-stem-cell transplantation (hsct);, congenital aids with recurrent bacterial infections. , immunomodulation in adults, children and adolescents (0-18 years) in: , primary immune thrombocytopenia (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, guillain barré syndrome;, kawasaki disease.

Euroopa Liit - norra - EMA (European Medicines Agency)

csl behring gmbh - human normal immunoglobulin (scig) - immunologiske mangelsyndrom - immune sera og immunglobuliner, - replacement therapy in adults, children and adolescents (0-18 years) in:- primary immunodeficiency syndromes with impaired antibody production (see section 4. - secondary immunodeficiencies (sid) in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure (psaf)* or serum igg level of.

Euroopa Liit - norra - EMA (European Medicines Agency)

baxalta innovations gmbh - humant normalt immunglobulin - immunologiske mangelsyndrom - immune sera og immunglobuliner, - erstatning terapi hos voksne, barn og ungdom (0-18 år) i:primær immunsvikt syndromer med nedsatt antistoff produksjon. hypogammaglobulinaemia og tilbakevendende bakterieinfeksjoner hos pasienter med kronisk lymfatisk leukemi (cll), som profylaktisk antibiotika har mislyktes eller er contra‑angitt. hypogammaglobulinaemia og residiverende bakterielle infeksjoner i myelomatose (mm) pasienter. hypogammaglobulinaemia i pasienter pre‑ og post‑allogen blodkreft stilk cellen transplantasjon (hsct).